Melanotan 2
MT-2
Melanotan 2 (MT-2) is the 'tanning peptide' — a synthetic α-MSH mimic that darkens skin without sun, which is why it's one of the most-searched research peptides. But it's also one of the most important to understand honestly, because its safety profile has real caveats. This guide covers how MT-2 works, what the research shows, its side effects and monitoring needs, dosing references and status.
Melanotan 2 quick facts
| Reported research dosing | 250mcg-1000mcg |
| Route | Subq |
| Cycle length | 4-12 Weeks (then maintenance) |
| Frequency | 1x Daily |
| Half-life | ~30-60 min |
| Forms | Injectable, Nasal |
| Evidence level | Anecdotal + animal |
Tans and raises libido, but the nausea/appetite/mole changes are real. Start tiny.
How Melanotan 2 works
MT-2 is a synthetic cyclic 7-amino-acid peptide that mimics alpha-melanocyte-stimulating hormone (α-MSH) — but it's up to 1000× more potent and hits four melanocortin receptors (MC1R, MC3R, MC4R, MC5R). Tanning comes from MC1R: MT-2 drives a cAMP cascade that ramps up tyrosinase and shifts pigment toward eumelanin (the darker, more photoprotective type) — producing UV-independent tanning, darkening skin without sun exposure. Its activity at MC3R/MC4R also explains its secondary effects: appetite suppression and increased libido.
What the research shows
Human data is small. The most-cited study is a 1998 placebo-controlled crossover in 10 men that documented dose-dependent increases in skin melanin (measured by spectrophotometry) with visible tanning within days, plus — notably — erections in 8 of 10 participants (which is how the sexual-health peptide PT-141 was later derived from it). But there is no large randomized trial showing safe, effective tanning in healthy adults, and MT-2 has no approved clinical indication.
Safety & side effects — read this part
MT-2 is a compound where the risks deserve real attention. Common effects include nausea (especially early and at higher doses), flushing, and spontaneous erections in men. The bigger concern is dermatological: MC1R activation causes existing moles to darken and can prompt new moles (nevi) — which is why regular skin/dermatology monitoring is considered essential, and why there's ongoing concern about melanoma risk. This is not a casual cosmetic — it warrants genuine caution.
Melanotan 2 dosing (research reference)
Research references escalating subcutaneous doses (the 1998 study used roughly 0.01–0.025 mg/kg), typically with a lower 'loading' phase to build the tan and a smaller maintenance dose to hold it — started low specifically to limit nausea. It's a lyophilized powder reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. This summarizes existing references for education only, not dosing advice or a recommendation for human use.
Related compounds
MT-2 is part of the melanocortin family. Its erection side-effect led directly to PT-141 (bremelanotide), which was developed to target sexual desire specifically. Melanotan 1 (afamelanotide) is a related, more MC1R-selective tanning peptide with a cleaner side-effect profile.
Legal & regulatory status
Melanotan 2 has no approved clinical indication and is not FDA-approved; it's sold as a research compound (research use only) and its sale for human use is restricted or banned in several countries. Given the melanoma-monitoring concerns, this is one to approach especially carefully. Follow the laws that apply to you.
✅ Clinically validated
- No randomised human trials. This is a research compound sold for laboratory use, and nobody has funded the trial that would change that — not because it failed one, but because there is no route to a return on it. Read the correlative and theoretical tiers as the actual evidence base rather than as a consolation prize.
- Afamelanotide — a closely related, more selective melanocortin analogue — IS approved (Scenesse) for erythropoietic protoporphyria, which establishes that the receptor family can be safely targeted in humans. It does not validate the unselective version.
📊 Correlative data
- Heavy real-world use with a consistent and well-documented reported profile: nausea and facial flushing on early doses, spontaneous erections, appetite suppression, and reliable tanning with far less UV exposure.
- The case reports are the part worth reading. Published literature documents new and changing melanocytic naevi, and at least one melanoma diagnosed in a user. Causation is unproven; the biological plausibility is not in question.
🧪 Theoretical / extrapolated
- A non-selective melanocortin agonist — MC1R drives melanogenesis, MC3R/MC4R drive the libido and appetite effects. The lack of selectivity is why one compound produces such an unrelated-looking set of effects.
- The mechanism predicts the mole issue directly: stimulating melanocytes systemically is the point, and existing naevi contain melanocytes. That is the argument for a skin check before and during, and it comes from the pharmacology rather than from caution.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
Melanotan 2 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are melanocortin receptor agonists and they are not selective, which is the whole safety story. MC1R gives the tanning. MC4R gives the nausea, the flushing and the erections. You do not get to choose which receptors respond.
- The mole question is the one that matters. These drive melanogenesis systemically — existing naevi commonly darken and new ones can appear. That is not itself cancer, but it makes melanoma surveillance harder precisely in people using a tanning agent.
What has actually been reported
- Nausea in the first hours after dosing is very common and usually settles with repeated exposure. Facial flushing, spontaneous erections and appetite suppression are all frequently reported.
- Case reports exist of melanoma diagnosed in Melanotan users. Causation is not established and the population self-selects for sun exposure — but 'unproven' is not 'reassuring' here.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Get a full-body skin check before you start, and photograph your moles. This is the whole mitigation. The predicted problem is that melanogenesis makes surveillance harder — a dated set of baseline photographs is what makes 'has this changed?' answerable later.
- Start at a fraction of the intended dose. The nausea and flushing are MC4R effects that attenuate with exposure, so almost everyone who has a miserable first experience simply started too high.
- Dose in the evening. If the nausea lands, you sleep through the worst of it.
- Sun protection does not become optional because you tan faster. Melanin is partial protection, and the tan is not the part that matters here — the mole surveillance is.
- Any new lesion, or an existing one that changes shape, colour or border, is a dermatologist appointment rather than a forum question.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- No routine marker tracks this. The monitoring here is dermatological, not haematological — get a skin check and photograph your moles before you start.
Don't run this if
- Personal or family history of melanoma, or many atypical moles.
- Any pigmented lesion you have not had looked at.
The honest unknown
- Whether driving melanogenesis for years changes melanoma risk in humans. Nobody has run that study and it is not obvious anyone will.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Food is not a factor — pick a time you will keep
Nothing you eat touches a subcutaneous injection, so there is no meal to plan around. What does matter is a fixed slot: the commonest reason an injectable protocol underperforms is missed doses, not mistimed ones.
With a short half-life, dose it near the effect you want rather than at a fixed hour.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
Melanotan 2 reconstitution calculator
Research reconstitution calculator
Where to get Melanotan 2
Buy Melanotan 2 at AminoWell USA →Melanotan 2 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What Melanotan 2 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Blood pressure is the thing to watch here and it is not a lab — melanocortin agonists can raise it transiently after dosing.
What to do: Take blood pressure before and an hour after a dose the first few times. That tells you more than any panel.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for Melanotan 2 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The mechanism-predicted concern that matters is not on a blood panel: melanocortin agonists stimulate melanocytes, so existing moles darkening or changing is the signal to take seriously, and a skin check before starting is the version of a baseline that applies here.
Bloodwork to run alongside Melanotan 2
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | General baseline — but bloodwork is not the monitoring that matters here |
Check results you already have → · All 102 markers A–Z
Melanotan 2 — frequently asked questions
What is Melanotan 2?
Melanotan 2 (MT-2) is a synthetic α-MSH-mimicking peptide that darkens skin without sun by activating melanocortin receptors. It's researched as a 'tanning peptide' and also causes appetite suppression and increased libido.
How does Melanotan 2 make you tan?
It activates MC1R, driving a cAMP cascade that boosts tyrosinase and shifts pigment toward eumelanin — producing UV-independent tanning (darkening without sun exposure).
Is Melanotan 2 safe?
It has real caveats. Common effects are nausea, flushing and spontaneous erections; more importantly, it darkens existing moles and can prompt new ones, so dermatology monitoring is considered essential and melanoma risk is a genuine concern. There's no large safety trial in healthy adults.
How is Melanotan 2 dosed?
Research references escalating subcutaneous doses (the key study used ~0.01–0.025 mg/kg), usually a low loading phase then a maintenance dose, started low to limit nausea. Reconstituted with bacteriostatic water (see calculator). Educational only, not dosing advice.
What's the difference between Melanotan 2 and PT-141?
PT-141 (bremelanotide) was derived from Melanotan 2's erection side effect and engineered to target sexual desire specifically. MT-2 is primarily a tanning peptide; PT-141 is a sexual-health peptide.
Is Melanotan 2 FDA-approved?
No. It has no approved clinical indication, is not FDA-approved, and its sale for human use is restricted or banned in several countries. It's sold as a research compound.
References & further reading
- Melanotan II: mechanism, effects & research studies (Peptpedia)
- Melanotan 2: reviews, clinical trials and safety (Peptides.org)
- Melanotan II: mechanism, evidence, risks and alternatives (PeakedLabs)
Want Coach Cam's exact Melanotan 2 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What Melanotan 2 is used for
Melanotan 2 appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.